AVROBIO Q1 net loss $29.8M, cash runway into Q1 2024; cystinosis trial fully enrolled

Tectonic Therapeutic, Inc.

2023-Q1 EPS reported -$0.68

Net loss $29.8M in Q1 2022, up from $26.9M in Q1 2021.
R&D expenses $19.3M; G&A $10.2M including severance costs.
Cash and equivalents $161.7M as of Mar 31, 2022; runway into Q1 2024.
Cystinosis Phase 1/2 trial fully enrolled (6 patients); new data at ASGCT.
Plan to start company-sponsored trials in 2023 for cystinosis, Gaucher type 3, Hunter, Pompe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.